ImpediMed Limited Stock price

Equities

IPD

AU000000IPD8

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.092 AUD +6.98% Intraday chart for ImpediMed Limited -3.16% -36.55%
Sales 2024 * 11.7M 7.59M Sales 2025 * 21.2M 13.76M Capitalization 174M 113M
Net income 2024 * -21M -13.63M Net income 2025 * -14M -9.08M EV / Sales 2024 * 12.8 x
Net cash position 2024 * 24.26M 15.75M Net cash position 2025 * 14.4M 9.34M EV / Sales 2025 * 7.53 x
P/E ratio 2024 *
-9.29 x
P/E ratio 2025 *
-14.9 x
Employees 76
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day+6.98%
1 week-1.08%
Current month+10.84%
1 month+9.52%
3 months-33.09%
6 months-48.89%
Current year-36.55%
More quotes
1 week
0.08
Extreme 0.084
0.09
1 month
0.08
Extreme 0.081
0.12
Current year
0.08
Extreme 0.076
0.16
1 year
0.08
Extreme 0.076
0.24
3 years
0.05
Extreme 0.049
0.24
5 years
0.03
Extreme 0.032
0.35
10 years
0.03
Extreme 0.032
1.82
More quotes
Managers TitleAgeSince
Chief Executive Officer - Jan. 07
Director of Finance/CFO - 23-09-27
Chief Operating Officer - 18-07-01
Members of the board TitleAgeSince
Chief Executive Officer - Jan. 07
Director of Finance/CFO - 23-09-27
Chairman - 23-09-27
More insiders
Date Price Change Volume
24-03-28 0.092 +6.98% 1 158 154
24-03-27 0.086 0.00% 784,145
24-03-26 0.086 -1.15% 1,049,915
24-03-25 0.087 -1.14% 1,645,633
24-03-22 0.088 -5.38% 3,208,157

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
ImpediMed Limited is an Australia-based medical software technology company. The Company is engaged in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services with a focus on the early detection of lymphoedema and heart failure. It measures, monitors and manages fluid status and tissue composition using BIS. The Company's SOZO digital health platform uses BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its SFB7 measures fluid status and tissue composition for clinical and research applications. It offers ImpediVET, a single-channel, tetrapolar BIS device that measures fluid status and tissue composition for veterinary applications from laboratory research to clinic. SOZO applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp analysis, and HF-Dex analysis for heart failure.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.086 AUD
Average target price
0.1814 AUD
Spread / Average Target
+110.90%
Consensus
  1. Stock
  2. Equities
  3. Stock ImpediMed Limited - Australian S.E.